CH618707A5 - - Google Patents

Download PDF

Info

Publication number: CH618707A5
Authority: CH; Switzerland
Prior art keywords: compound; arabino; formula; cells; hours
Prior art date: 1974-10-29

Application number

CH1395075A

Other languages

German (de)

English (en)

Inventor

Federico Arcamone

Alberto Bargiotti

Giuseppe Cassinelli

Aurelio Di Marco

Original Assignee

Farmaceutici Italia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-10-29

Filing date

1975-10-28

Publication date

1980-08-15

1975-10-28 Application filed by Farmaceutici Italia filed Critical Farmaceutici Italia

1980-08-15 Publication of CH618707A5 publication Critical patent/CH618707A5/de

Links

150000001875 compounds Chemical class 0.000 description 21
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
229910052739 hydrogen Inorganic materials 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
239000000243 solution Substances 0.000 description 9
238000000034 method Methods 0.000 description 8
125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000000259 anti-tumor effect Effects 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
YOFDHOWPGULAQF-MQJDWESPSA-N (7s,9s)-9-acetyl-6,7,9,11-tetrahydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1[C@@](O)(C(C)=O)C[C@H](O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-MQJDWESPSA-N 0.000 description 4
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 4
YOFDHOWPGULAQF-UHFFFAOYSA-N Daunomycin-Aglycone Natural products C1C(O)(C(C)=O)CC(O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-UHFFFAOYSA-N 0.000 description 4
241000713862 Moloney murine sarcoma virus Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
208000006268 Sarcoma 180 Diseases 0.000 description 4
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
238000001816 cooling Methods 0.000 description 3
229930182470 glycoside Natural products 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
238000001819 mass spectrum Methods 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002927 anti-mitotic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CH1395075A 1974-10-29 1975-10-28 CH618707A5 (2)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB4664474A GB1470860A (en)	1974-10-29	1974-10-29	Anthracycline glycosides

Publications (1)

Publication Number	Publication Date
CH618707A5 true CH618707A5 (2)	1980-08-15

Family

ID=10442049

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CH1395075A CH618707A5 (2)	1974-10-29	1975-10-28
CH94680A CH621799A5 (2)	1974-10-29	1980-02-06

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CH94680A CH621799A5 (2)	1974-10-29	1980-02-06

Country Status (17)

Country	Link
US (1)	US4025623A (2)
JP (2)	JPS5951559B2 (2)
AT (1)	AT340591B (2)
AU (1)	AU498511B2 (2)
BE (1)	BE834939A (2)
CA (1)	CA1046509A (2)
CH (2)	CH618707A5 (2)
DE (1)	DE2548087A1 (2)
DK (1)	DK146803C (2)
ES (1)	ES442144A1 (2)
FR (1)	FR2289203A1 (2)
GB (1)	GB1470860A (2)
NL (1)	NL7512489A (2)
SE (1)	SE423996B (2)
SU (2)	SU646913A3 (2)
YU (2)	YU37119B (2)
ZA (1)	ZA756732B (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1506200A (en) *	1975-04-30	1978-04-05	Farmaceutici Italia	Glycosides
GB1502121A (en) *	1975-08-02	1978-02-22	Farmaceutici Italia	Anthracyclines
GB1524468A (en) *	1976-07-13	1978-09-13	Farmaceutici Italia	Anthracylines
GB1561507A (en) *	1976-11-17	1980-02-20	Farmaceutici Italia	Snthracycline disaccharides
GB1573037A (en) *	1977-05-05	1980-08-13	Farmaceutici Italia	Anthracyclines
GB1573036A (en) *	1977-05-05	1980-08-13	Farmaceutici Italia	Anthracyclines
US4181795A (en) *	1978-05-22	1980-01-01	Purdue Research Foundation	Daunosamine synthesis
US4203976A (en) *	1978-08-02	1980-05-20	Merck & Co., Inc.	Sugar derivatives of C-076 compounds
US4303785A (en) *	1978-08-05	1981-12-01	Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai	Antitumor anthracycline antibiotics
JPS5756494A (en) *	1980-09-22	1982-04-05	Microbial Chem Res Found	New anthracyclin derivative
JPS6130464U (ja) *	1984-07-26	1986-02-24	武夫安田	食器洗い用具
JPH01207028A (ja) *	1987-02-09	1989-08-21	Tomiko Saito	タワシと容器
JPH0261920U (2) *	1988-10-28	1990-05-09
JP3035035U (ja) *	1996-04-26	1997-03-11	裕敬丸子	把手のあるスポンジ
EP1036797B1 (en) *	1997-12-05	2010-11-17	Mercian Corporation	Crystalline anthracycline antibiotic and process for producing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3803124A (en) *	1968-04-12	1974-04-09	Farmaceutici It Soc	Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
BE793976A (fr) *	1972-01-13	1973-05-02	Parke Davis & Co	Nouvelles polyamines et procede pour les preparer

1974
- 1974-10-29 GB GB4664474A patent/GB1470860A/en not_active Expired
1975
- 1975-10-10 US US05/621,582 patent/US4025623A/en not_active Expired - Lifetime
- 1975-10-24 NL NL7512489A patent/NL7512489A/xx not_active Application Discontinuation
- 1975-10-24 AT AT812975A patent/AT340591B/de not_active IP Right Cessation
- 1975-10-24 YU YU2695/75A patent/YU37119B/xx unknown
- 1975-10-27 DK DK482175A patent/DK146803C/da not_active IP Right Cessation
- 1975-10-27 SE SE7512005A patent/SE423996B/xx unknown
- 1975-10-27 FR FR7532753A patent/FR2289203A1/fr active Granted
- 1975-10-27 SU SU752184006A patent/SU646913A3/ru active
- 1975-10-27 AU AU86040/75A patent/AU498511B2/en not_active Expired
- 1975-10-27 ZA ZA00756732A patent/ZA756732B/xx unknown
- 1975-10-28 CA CA238,713A patent/CA1046509A/en not_active Expired
- 1975-10-28 BE BE161309A patent/BE834939A/xx not_active IP Right Cessation
- 1975-10-28 ES ES442144A patent/ES442144A1/es not_active Expired
- 1975-10-28 JP JP50128991A patent/JPS5951559B2/ja not_active Expired
- 1975-10-28 DE DE19752548087 patent/DE2548087A1/de not_active Withdrawn
- 1975-10-28 CH CH1395075A patent/CH618707A5/de not_active IP Right Cessation
1976
- 1976-08-10 SU SU762387269A patent/SU628822A3/ru active
1980
- 1980-02-06 CH CH94680A patent/CH621799A5/de not_active IP Right Cessation
1981
- 1981-12-14 YU YU02933/81A patent/YU293381A/xx unknown
1983
- 1983-11-11 JP JP58211116A patent/JPS6056720B2/ja not_active Expired

Also Published As

Publication number	Publication date
DK146803B (da)	1984-01-09
AU8604075A (en)	1977-05-05
DK482175A (da)	1976-04-30
FR2289203A1 (fr)	1976-05-28
JPS5951559B2 (ja)	1984-12-14
CA1046509A (en)	1979-01-16
SE423996B (sv)	1982-06-21
US4025623A (en)	1977-05-24
YU269575A (en)	1983-04-27
AT340591B (de)	1977-12-27
AU498511B2 (en)	1979-03-15
DK146803C (da)	1984-06-18
ZA756732B (en)	1976-10-27
SU628822A3 (ru)	1978-10-15
JPS6056720B2 (ja)	1985-12-11
SU646913A3 (ru)	1979-02-05
CH621799A5 (2)	1981-02-27
ATA812975A (de)	1977-04-15
ES442144A1 (es)	1977-08-01
BE834939A (fr)	1976-04-28
JPS5168561A (2)	1976-06-14
YU37119B (en)	1984-08-31
YU293381A (en)	1985-04-30
FR2289203B1 (2)	1978-11-10
NL7512489A (nl)	1976-05-04
DE2548087A1 (de)	1976-05-06
SE7512005L (sv)	1976-04-30
GB1470860A (en)	1977-04-21
JPS59104397A (ja)	1984-06-16

Legal Events

Date	Code	Title	Description
1986-06-30	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE2525633C3 (2)	1979-10-18
DE2618822C3 (de)	1983-04-28	Anthracyclin-Glycoside und Verfahren zu deren Herstellung
DE2642837C3 (de)	1982-08-12	Anthracyclinglycoside und Verfahren zu deren Herstellung
DE2510866C3 (de)	1980-08-14	4'-epi-Adriamycin a - und ß -Anomer, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69710573T2 (de)	2002-10-31	Morpholinyl-anthracyclinderivate
DE2548087A1 (de)	1976-05-06	Antitumorglycoside und verfahren zu deren herstellung
EP0002680B1 (de)	1981-02-11	4-Spectinomycylamin und seine physiologisch verträgliche Salze, Verfahren zur Herstellung und diese Stoffe enthaltende Arzneimittel
DE2726839B2 (de)	1979-08-30	l-N-Hydroxyalkyl-kanamycine A und -kanamycine B, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DD224596A5 (de)	1985-07-10	Procede de preparation de benzyl-phenyl-osides utiles en therapeutique
DE2716533B2 (de)	1981-04-30	N-Acetylierte oder -halogenacetylierte Kanamycine A und B, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2422254A1 (de)	1974-11-28	Aminoglycosidderivate und deren salze, verfahren zu deren herstellung und pharmazeutische praeparate
DE2735455C3 (de)	1982-10-28	Daunomycinanaloga, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2836913A1 (de)	1979-03-15	Desoxyneamine
CH632770A5 (de)	1982-10-29	Verfahren zur herstellung von antitumorglycosiden.
CH626896A5 (2)	1981-12-15
DE2942818C2 (de)	1986-05-22	4'-C-Methyl-4'-O-methyl-daunorubicin und -doxorubicin und deren 4'-Epimere sowie diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
AT341096B (de)	1978-01-25	Verfahren zur herstellung des neuen 4'-epi -6'- hydroxyadriamycins
DE69106459T2 (de)	1995-05-18	2-Acyloxy-4-morpholinyl-Anthracyclin.
US5374711A (en)	1994-12-20	Chemical modification of 2"-amino group in elsamicin a
DE2519157A1 (de)	1975-11-20	Verfahren zur herstellung von glycosiden mit antitumorwirksamkeit
DE2510926C3 (de)	1980-03-13	4'-epi-Daunomycuie, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE3905431A1 (de)	1989-09-07	Neue 4-demethyl-4-0-(p-fluorobenzolsulfonyl)anthracyclinglycoside
US5237055A (en)	1993-08-17	Chemical modification of 2"-amino group in elsamicin A
CH644095A5 (de)	1984-07-13	Verfahren zur herstellung von 2,4-diaminobuttersaeure oder 4-amino-2-hydroxybuttersaeure.
DE3106463A1 (de)	1982-02-11	Neue derivate des kanamycin a sowie verfahren zu herstellung derselben